| scholarly article | Q13442814 |
| P2093 | author name string | E S Moland | |
| K S Thomson | |||
| P2860 | cites work | Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center | Q44685672 |
| Beta-lactamase-mediated resistance and opportunities for its control | Q47750408 | ||
| Animal models of pneumonia for evaluation of antimicrobial therapy. | Q53899157 | ||
| In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance. | Q54158188 | ||
| A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. | Q54316090 | ||
| Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. | Q54380570 | ||
| Bacterial counts in cerebrospinal fluid of children with meningitis | Q67295786 | ||
| Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins | Q70805653 | ||
| Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit | Q71114922 | ||
| Treatment failure due to extended spectrum beta-lactamase | Q71119710 | ||
| Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis | Q77292922 | ||
| A functional classification scheme for beta-lactamases and its correlation with molecular structure | Q24677460 | ||
| Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate | Q33752745 | ||
| Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. | Q33972587 | ||
| Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae | Q33977146 | ||
| Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium | Q34047473 | ||
| Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). | Q34135508 | ||
| Extended-spectrum beta-lactamases: how big is the problem? | Q34347094 | ||
| Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics | Q35111391 | ||
| In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins | Q35114789 | ||
| Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae | Q35136019 | ||
| Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases | Q35254248 | ||
| Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility | Q35281765 | ||
| Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids | Q35359453 | ||
| Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats | Q35652730 | ||
| In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin | Q35810522 | ||
| In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae | Q35822646 | ||
| Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant | Q35896975 | ||
| Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. | Q36527781 | ||
| More extended-spectrum beta-lactamases | Q37520309 | ||
| Epidemiology of extended spectrum beta-lactamases | Q39353873 | ||
| A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group | Q39537314 | ||
| Characterization of beta-lactamases in situ on polyacrylamide gels | Q39851784 | ||
| Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase | Q40284915 | ||
| TEM- and SHV-derived extended-spectrum beta-lactamases: relationship between selection, structure and function | Q40538157 | ||
| The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics | Q40576484 | ||
| Cefepime: the next generation? | Q40770615 | ||
| Extended-spectrum plasmid-mediated beta-lactamases | Q40936228 | ||
| Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. | Q41037501 | ||
| In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. | Q41062299 | ||
| The use of analytical isoelectric focusing for detection and identification of beta-lactamases | Q41985418 | ||
| Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae | Q43665731 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Enterobacteriaceae | Q380136 |
| P304 | page(s) | 3548-3554 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae | |
| P478 | volume | 45 |
| Q34750112 | Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances |
| Q37037740 | An epidemic of plasmids? Dissemination of extended-spectrum cephalosporinases among Salmonella and other Enterobacteriaceae |
| Q49376241 | Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation |
| Q44943295 | Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases |
| Q51547630 | Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. |
| Q36523688 | Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens |
| Q28546654 | Bacterial temporal dynamics enable optimal design of antibiotic treatment |
| Q94563529 | Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods - ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii |
| Q35715650 | Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia |
| Q89598600 | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| Q40612416 | Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia. |
| Q35833277 | Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak |
| Q44640091 | Clinical and Microbiologic Analysis of a Hospital's Extended‐Spectrum β‐Lactamase‐Producing Isolates Over a 2‐Year Period |
| Q34680546 | Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species |
| Q36726208 | Collective antibiotic tolerance: mechanisms, dynamics and intervention |
| Q37733597 | Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo i |
| Q30386797 | Crowdsourced Data Indicate Widespread Multidrug Resistance in Skin Flora of Healthy Young Adults. |
| Q24612271 | Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa |
| Q33235526 | Detection and genotyping of SHV beta-lactamase variants by mass spectrometry after base-specific cleavage of in vitro-generated RNA transcripts |
| Q42929547 | Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter isolates |
| Q42799124 | Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures |
| Q33682185 | Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis. |
| Q34402917 | Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis |
| Q40116346 | Ecthyma gangrenosum caused by Citrobacter freundii |
| Q42738176 | Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations |
| Q40470351 | Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology |
| Q43137201 | Efficacy of cefepime therapy for Enterobacter bacteraemia, with special emphasis on febrile neutropenic patients |
| Q35600060 | Emergence of community-acquired extended-spectrum beta-lactamase Escherichia coli (ESBLEC) in Honolulu: a case series of three individuals with community-acquired ESBLEC bacteriuria |
| Q35023326 | Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility |
| Q34201311 | Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. |
| Q35090146 | Expert systems in clinical microbiology |
| Q35056715 | Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment |
| Q42737953 | Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance. |
| Q37091253 | Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern |
| Q24534999 | Extended-spectrum beta-lactamases: a clinical update |
| Q34159849 | Extended-spectrum ß-lactamases in gram negative bacteria |
| Q35558473 | Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control |
| Q33769534 | Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q54379255 | High frequency of -lactam susceptibility in CTX-M-type extended-spectrum- -lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations |
| Q36670187 | High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. |
| Q39577254 | Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs |
| Q31102336 | Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study |
| Q39773769 | Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study |
| Q43962900 | Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. |
| Q40727206 | In Vitro Activity of Imipenem and Colistin against a Carbapenem-Resistant Klebsiella pneumoniae Isolate Coproducing SHV-31, CMY-2, and DHA-1. |
| Q46738447 | In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli |
| Q43188135 | In vitro interaction between cefepime and amoxicillin-clavulanate against extended-spectrum β-lactamase-producing Escherichia coli |
| Q41779878 | Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints |
| Q42277205 | Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. |
| Q37694529 | Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices |
| Q36785886 | Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. |
| Q44720612 | International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests |
| Q24794095 | Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in Enterobacteriaceae |
| Q37139730 | Meropenem: a review of its use in the treatment of serious bacterial infections. |
| Q38113887 | Methicillin resistant staphylococci and broad-spectrum β-lactamase producing Enterobacteriaceae in horses |
| Q44135229 | Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection |
| Q35960721 | Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia |
| Q64939222 | Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration. |
| Q38620812 | Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients. |
| Q56777538 | No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia |
| Q34753336 | Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases |
| Q55644807 | Optimization of E. coli Inactivation by Benzalkonium Chloride Reveals the Importance of Quantifying the Inoculum Effect on Chemical Disinfection. |
| Q53811523 | Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options. |
| Q58549610 | Phenotypic characterization and whole genome analysis of extended-spectrum beta-lactamase-producing bacteria isolated from dogs in Germany |
| Q47315442 | Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms |
| Q34648809 | Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae |
| Q38934400 | Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications |
| Q34991064 | Quality control for beta-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain |
| Q33776486 | Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli |
| Q44955664 | Retrospective study of clinical outcomes with extended-spectrum beta-lactamases--a different interpretation |
| Q42167308 | Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae |
| Q33686219 | Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. |
| Q43077883 | Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods |
| Q88764059 | The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination |
| Q38864569 | The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections |
| Q37892237 | The challenges of antimicrobial drug resistance in Greece |
| Q37563005 | The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock |
| Q38497797 | The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae |
| Q38875315 | The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies |
| Q37555757 | The use of carbapenems in the treatment of serious infections |
| Q52695014 | Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. |
| Q38185648 | Treatment of multidrug-resistant Gram-negative infections in children |
| Q38739545 | Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria |
| Q39353134 | Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population |
| Q38532531 | Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment? |
| Q38365280 | β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? |
| Q38264182 | β-lactam/β-lactamase inhibitor combinations: from then to now. |
Search more.